1. Catalog
  2. New Treatment Paradigms in Primary Biliary Cholang ...
New Treatment Paradigms in Primary Biliary Cholangitis (PBC)
Image For Activity Cover
Create Account
Availability
On-Demand
Cost
$0.00
Credit Offered
0.5 AMA PRA Category 1 Credit
0.5 ABIM MOC Point
0.5 ABP MOC Point
  • Description
  • Learning Objectives
  • Accreditation Information
  • Faculty and Disclosures
  • Privacy Policy
  • Recommended
In this case-based activity, Drs. Craig Lammert and David Assis, leaders of the CALD SIG, discuss two newly approved therapies for patients with primary biliary cholangitis. They will explore a variety of patient scenarios involving the diagnosis and treatment of patients with PBC to explore the range of available therapies, and how best to approach each clinical encounter.
Upon completion of this activity, participants should be able to:
  • Describe clinical considerations when diagnosing and treating patients with PBC.
  • Discuss the care of patients with PBC with a variety of co-morbidities.
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date:   September 23, 2024
Expiration Date:  September 23, 2026

COPYRIGHT:  All faculty in this activity have given their permission for publication ©2024 AASLD.
This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the speaker shall disclose to the audience that the product is not labeled for the use under discussion or that the product is still investigational.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The following faculty have disclosed relationships:

David Assis, MD:
Research Grants: Gilead

Craig Lammert, MD:
Scientific Consultant: Kezaar Life Sciences, Eli Lilly 

Steven Folstein, MFA M.Ed.:
Nothing to Disclose
Powered By